8-K: Runway Growth to Acquire SWK Holdings in $220M Deal

Runway Growth Finance Corp. announced a definitive merger agreement to acquire SWK Holdings Corporation, expanding its healthcare and life sciences portfolio and projecting mid-single-digit NII accretion.

Summary

• Runway Growth Finance Corp. (RWAY) has entered into a definitive merger agreement to acquire SWK Holdings Corporation (SWKH), a life science focused specialty finance company.
• The transaction is structured as a multi-step merger, which will result in SWK becoming a wholly-owned subsidiary of Runway Growth.
• The estimated purchase price for SWK is approximately $220 million, based on SWK's June 30, 2025 financials and including estimated transaction expenses.
• Consideration for SWK shareholders will consist of a fixed stock component of $75.5 million in Runway Growth shares (valued at closing NAV per share) and approximately $145 million in cash.
• Runway Growth Capital LLC, Runway Growth's external investment adviser, will contribute an additional $9 million in cash for distribution to SWK stockholders.
• SWK's portfolio comprises 22 companies with an approximate fair value of $242 million, as estimated by Runway Growth as of August 15, 2025.
• The transaction is anticipated to close in late 2025 or the first quarter of 2026, pending SWK shareholder and regulatory approvals, along with other customary closing conditions.

Sentiment

Score: 8

Explanation: The filing announces a strategic acquisition that is expected to be accretive to NII, expand the portfolio in a key sector, and enhance the financial profile of Runway Growth. While standard merger risks are noted, the overall tone and projected outcomes are highly positive for the acquirer.

Positives

• Expands Runway Growth's exposure to the healthcare and life sciences sector, increasing related investments to approximately 31% of the portfolio from 14% as of June 30, 2025.
• Drives portfolio scale and diversification, increasing total assets to $1.3 billion pro forma for the acquisition.
• Expected to generate mid-single-digit run-rate Net Investment Income (NII) accretion during the first full quarter following the transaction close.
• Anticipated improvements in dividend coverage and Return on Equity (ROE).
• Enhances Runway Growth's financial profile and expands its pro-forma leverage ratio, supporting continued risk-adjusted returns.
• Broadens Runway Growth's shareholder base and increases trading liquidity of common shares through the issuance of $75.5 million in Runway Growth shares.
• Reinforces Runway Growth's strategy for disciplined growth and venture debt investing with a focus on excellent credit quality.
• Supported by the $10 billion BC Partners Credit platform, enabling both organic and inorganic growth strategies.

Risks

• Uncertainty regarding the ability of the parties to consummate the mergers on the expected timeline, or at all.
• Risk that expected synergies and savings associated with the mergers may not be fully realized.
• Inability to realize anticipated benefits of the mergers, including the expected elimination of certain expenses and costs.
• Uncertainty regarding the percentage of SWK's stockholders voting in favor of the transaction.
• Possibility that competing offers or acquisition proposals will be made.
• Risk that any or all of the various conditions to the consummation of the mergers may not be satisfied or waived.
• Risks related to diverting management's attention from ongoing business operations.
• Potential termination of the merger agreement.
• Uncertainty regarding future operating results and net investment income projections of the combined company.
• Risk that stockholder litigation in connection with the mergers may result in significant costs of defense and liability.
• Impact of the merger on the depth of trading in Runway's shares of common stock post-closing.
• Risks associated with the research and development of medical products, including the high degree of risk and low commercialization rate.

Future Outlook

The combined company expects to enhance its earnings power, achieve mid-single-digit Net Investment Income (NII) accretion, improve dividend coverage and Return on Equity (ROE), and expand its pro-forma leverage ratio. Runway Growth plans to pursue continued growth through both organic and inorganic strategies, supported by the BC Partners Credit platform, and aims to increase its shareholder base and total assets to $1.3 billion.

Management Comments

• "This transaction meaningfully advances our strategy to diversify and optimize our portfolio by adding SWK’s high-quality investments in the key sectors of healthcare and life sciences." David Spreng, Founder and CEO of Runway Growth.
• "At the same time, we are enhancing our earnings power, more than offsetting the anticipated loan repayments we previously signaled, and we expect to deliver mid-single-digit NII accretion." David Spreng.
• "This transaction reinforces the strength of Runway Growth’s portfolio as we work to generate long-term value for our shareholders through disciplined growth and venture debt investing with a focus on excellent credit quality in the sectors we know best." David Spreng.
• "Looking ahead, and with the full support of BC Partners Advisors L.P., we are pursuing growth through both organic and inorganic strategies as a permanent capital vehicle backed by the $10 billion BC Partners Credit platform." David Spreng.
• "We are doing all of this while growing our shareholder base, improving our existing robust portfolio metrics and increasing our total assets to $1.3 billion pro forma with the SWK merger transaction." David Spreng.

Industry Context

This acquisition positions Runway Growth to significantly expand its presence in the high-growth healthcare and life sciences specialty finance sector, a strategic move for venture debt providers seeking diversification and enhanced credit quality. The transaction reflects a broader trend of consolidation and strategic partnerships within the specialized lending market, particularly as companies leverage permanent capital vehicles and institutional backing, such as the BC Partners Credit platform, to scale operations and optimize portfolios.

Management Changes

Corporate Governance

Legal Proceedings

• Potential stockholder litigation in connection with the mergers, which may result in significant costs of defense and liability.

Stakeholder Impact

• SWK Shareholders: Will receive a combination of Runway Growth shares and cash, providing liquidity and continued exposure to the combined entity.
• Runway Growth Shareholders: Expected to benefit from NII accretion, improved dividend coverage, enhanced ROE, and a more diversified, scaled portfolio.
• Employees: Members of SWK's healthcare and life sciences teams will be added to Runway Growth Capital's investment and deal sourcing teams, indicating integration and potential growth opportunities.
• Customers (Portfolio Companies): The combined entity will have a larger balance sheet and broader capabilities, potentially offering more robust financing solutions.

Next Steps

• SWK shareholder approval of the transaction.
• Regulatory approvals for the merger.
• Filing of a registration statement on Form N-14 by Parent (Runway Growth) with the SEC.
• Mailing of a definitive proxy statement/prospectus to SWK stockholders.
• Closing of the transaction, expected in late 2025 or the first quarter of 2026.
• Conference call to discuss the transaction on October 10, 2025.

Key Dates

Recommendation

The acquisition of SWK Holdings by Runway Growth Finance Corp. is a highly strategic move that is expected to significantly enhance Runway Growth's financial profile and market position. The projected mid-single-digit NII accretion, substantial increase in total assets to $1.3 billion, and diversification into the high-growth healthcare and life sciences sector (increasing portfolio exposure from 14% to 31%) are strong indicators of future value creation. The transaction is non-dilutive to shareholders in terms of future growth blueprint and is backed by the robust BC Partners Credit platform. While standard merger risks exist, the clear financial benefits and strategic alignment suggest a strong positive outlook for Runway Growth's stock.

Keywords

Merger, Acquisition, Healthcare Finance, Life Sciences, Venture Debt, SWK Holdings, Runway Growth Finance, SEC Filing, Financial Services, Investment